RUTTEN; Hartmut

Patent Applications and Registrations

Patent applications and USPTO patent grants for RUTTEN; Hartmut.The latest application filed is for "substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)".

Company Profile

0.5.5

RUTTEN; Hartmut - Idstein DE
Rutten; Hartmut - Kronberg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Substituted Pyridones As Inhibitors Of Poly(adp-ribose) Polymerase (parp) App 20120202795 - WEINTRAUB; Philip M. ; et al.	2012-08-09
Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) Grant 8,173,682 - Weintraub , et al. May 8, 2	2012-05-08
Substituted Pyridones As Inhibitors Of Poly(adp-ribose) Polymerase (parp) App 20070032489 - Weintraub; Philip M. ; et al.	2007-02-08
Imidazolidine derivatives, their preparation and their use Grant 6,962,937 - Wehner , et al. November 8, 2	2005-11-08
Imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them Grant 6,680,333 - Wehner , et al. January 20, 2	2004-01-20
Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker Grant 6,593,352 - Weichert , et al. July 15, 2	2003-07-15
Novel imidazolidine derivatives, their preparation and their use App 20030109497 - Wehner, Volkmar ; et al.	2003-06-12
Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them App 20030073723 - Wehner, Volkmar ; et al.	2003-04-17
Use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substrates of the heart Grant 6,462,024 - Lang , et al. October 8, 2	2002-10-08
Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker App 20020123632 - Weichert, Andreas ; et al.	2002-09-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.